Real World Outcomes in Stage 1 HPV Oropharyngeal SCC: Northland MDM Review
Treatment decisions for early HPV-driven oropharyngeal squamous cell carcinoma can look clean on paper. In real clinics, they are shaped by age, deprivation, access to surgery, public and private capacity, feeding needs, pathology, patient preference, and the judgement of a multidisciplinary team.
That was the practical value of the invited paper presented by Dr John Chaplin at the NZOHNS meeting at the Cordis Hotel in Auckland on Thursday 29 October. The paper reviewed 182 patients with Stage 1 HPV-driven oropharyngeal squamous cell carcinoma, with a focus on how patients were selected for surgical and non-surgical treatment through the northern regional multidisciplinary meeting, or MDM.
The review was notable for its balance. There were 91 surgical patients and 91 non-surgical patients, giving a clear view of two real-world pathways. It also showed why outcomes from everyday practice need to be interpreted with care. These were not identical patient groups separated only by treatment type. They differed in age, deprivation, treatment setting, and access to transoral robotic surgery, known as TORS.
This article summarises the key findings and why they matter for Stage 1 HPV-driven oropharyngeal SCC care in Aotearoa New Zealand.
Why Stage 1 HPV-driven oropharyngeal SCC needs careful selection
HPV-driven oropharyngeal squamous cell carcinoma often has a better prognosis than HPV-negative disease, but that does not make treatment simple. The oropharynx includes areas such as the tonsil and base of tongue, where treatment can affect swallowing, speech, nutrition, taste, and quality of life.
For Stage 1 disease, the clinical question is rarely whether treatment is needed. It is usually which treatment sequence offers the best balance between cure and harm.
Common pathways include:
Primary surgery, often with TORS where suitable
Radiotherapy
Chemoradiotherapy
Surgery followed by observation
Surgery followed by adjuvant radiotherapy or chemoradiotherapy, depending on pathology
The appeal of surgery in selected patients is clear. If the cancer can be removed completely and pathology is favourable, some patients may avoid adjuvant treatment. That can reduce the total burden of therapy. It may also reduce feeding tube use, swallowing difficulty, and treatment time.
The challenge is that surgery does not always end treatment. If adverse features are found after resection, adjuvant radiotherapy or chemoradiotherapy may still be recommended. In those cases, the patient has had both surgery and non-surgical treatment, which can increase the overall treatment burden.
That is where the MDM matters. A well-functioning MDM brings together surgical, radiation oncology, medical oncology, radiology, pathology, nursing, allied health, and supportive care perspectives. It also keeps the discussion grounded in the person in front of the team, not just the tumour stage.
What the Northern Regional MDM review examined
Dr Chaplin’s invited paper was a retrospective review of 182 patients with Stage 1 HPV-driven oropharyngeal SCC. The emphasis was on patient selection at the northern regional MDM and how that selection related to treatment patterns and outcomes.
The two treatment groups were evenly sized:
Treatment pathway | Number of patients |
Surgical | 91 |
Non-surgical | 91 |
Total | 182 |
That equal split makes the review easier to read, but the groups were not the same. The non-surgical group had different baseline features, which are important when comparing outcomes.
The non-surgical patients were:
Older on average, 64 years compared with 60 years in the surgical group
More deprived
Nearly all treated in the public system
The surgical patients were:
Younger on average
Less deprived as a group
Treated in a mixed public-private setting, with about 50% treated publicly
Much more likely to have access to TORS, which was performed almost exclusively in private care
These differences matter because treatment outcomes do not only reflect the treatment itself. They also reflect who receives each treatment, what resources are available, and how quickly and safely care can be delivered.
This is one of the central messages of the review. Real-world cancer outcomes are shaped by clinical selection and system factors together.
The surgical and non-surgical groups were clinically different
The age gap between the groups was modest, but meaningful. A mean age of 64 years in the non-surgical group compared with 60 years in the surgical group suggests that older patients were more often directed away from surgery.
That may reflect several practical factors. Older patients may have more comorbidities, higher anaesthetic risk, more complex recovery needs, or tumours less suited to surgical access. Some may also prefer to avoid an operation if a non-surgical pathway is expected to offer comparable cancer control.
Deprivation also matters. The review found that non-surgical patients were more deprived. In New Zealand, deprivation can affect access to care in many ways, including transport, time off work, whānau support, health literacy, ability to attend repeated appointments, and access to private treatment options.
The public-private split is especially relevant. Nearly all non-surgical patients were treated publicly. By contrast, only about half of surgical patients were treated in the public system. TORS was almost exclusively performed in private.
That does not mean the MDM process was flawed. It does mean the data should be read with context. If a treatment option is more available in one setting than another, the treatment groups can differ in ways that reflect both clinical and system-level selection.
For clinicians and service planners, that is one of the most useful parts of the review. It highlights not only what treatment was chosen, but also where access may shape choice.
Surgery alone was more common than in E3311
One of the most striking findings was the proportion of surgical patients who avoided adjuvant treatment.
In this review, 34% of patients had surgery alone. That is a much higher proportion than in the E3311 study, where 11% of patients were treated with surgery alone.
That comparison is important, but it needs careful interpretation. E3311 was a clinical trial with defined eligibility, treatment arms, pathology rules, and study controls. The Northland MDM review reflects real-world practice, where the team selected patients based on clinical assessment and local context.
The higher surgery-alone rate suggests that patient selection through the MDM may have identified a group with favourable disease features, suitable anatomy, and a good chance of avoiding adjuvant treatment.
For those patients, surgery can offer a valuable path. If complete resection is achieved and pathology confirms low-risk features, observation may be appropriate. That avoids the added burden of radiotherapy or chemoradiotherapy.
The finding also raises an important service question. If surgery alone is a realistic outcome for a meaningful subset of patients, then equitable access to the surgical tools and expertise that make this possible becomes more than a technical issue. It becomes part of cancer care equity.
Feeding support showed a clear treatment burden signal
Supplementary feeding is a practical marker of treatment burden. It does not capture every aspect of swallowing function or quality of life like an MDADI 20 point, 4 domain validated questionnaire might do, but it gives a concrete view of how treatment affects day-to-day recovery.
In the review, patients who had surgery alone needed supplementary feeding just over 50% of the time, and the mean duration was 0.9 months.
That is a relatively short period. It suggests that, for selected patients, surgery alone may allow a faster return to oral intake and a lower nutrition-support burden.
By contrast, supplementary feeding was much more common among patients who required adjuvant treatment. That pattern fits clinical experience. Radiotherapy and particularly chemoradiotherapy to the oropharynx can cause mucositis, pain, altered taste, dry mouth, and swallowing difficulty. When these treatments follow surgery, the combined effect can be greater.
The key point is not that one pathway is always easier. Some patients tolerate radiotherapy well. Some surgical patients have difficult recoveries. Some tumours are simply not suitable for a surgery-first approach.
The more useful lesson is this: avoiding adjuvant treatment, when safe, appears to reduce the supportive care burden for selected patients.
That makes accurate pre-treatment selection and high-quality pathological assessment critical.
What the review suggests about the MDM process
The paper’s central argument was that MDM-guided selection can deliver strong outcomes in a real-world population, even when compared with a randomised study context.
That is a significant claim because randomised studies are often treated as the gold standard. They are essential, but they do not always reflect the full complexity of everyday practice. Trial populations can be narrower. Treatment access may be more controlled. Follow-up may be more structured. Patients with higher social or medical complexity may be under-represented.
Real-world reviews help answer a different question: what happens when evidence is applied across a regional population with all the usual variation in age, deprivation, access, anatomy, and preference?
In this review, the MDM appears to have played a central role in matching patients to treatment. Surgical patients were not simply those with Stage 1 HPV-driven disease. They were a selected group, likely chosen because surgery was technically feasible and had a reasonable chance of limiting further treatment.
The non-surgical group was also selected. Older and more deprived patients were more likely to receive non-surgical care, and nearly all were treated publicly. That reflects the role of the MDM in considering more than the tumour.
A good MDM does three things:
It tests whether a treatment is technically possible.
It asks whether that treatment is likely to reduce or increase total harm.
It considers whether the pathway is realistic for the patient and health system.
The Northland MDM review shows why that third point should not be treated as secondary. Access, deprivation, and setting can influence what care looks like in practice.
Why public and private access deserves attention
The finding that TORS was performed almost exclusively in private care is one of the most important system-level signals in the review.
TORS can be useful for selected oropharyngeal cancers because it allows transoral access to areas that were historically harder to reach without more invasive surgery. It may help some patients avoid adjuvant therapy, depending on margins, nodal disease, extranodal extension, and other pathology findings.
If access to TORS is limited mainly to private settings, then public patients may have fewer opportunities for a surgery-first pathway. That does not automatically mean they receive inferior care. Radiotherapy and chemoradiotherapy remain standard and effective treatments for many patients with HPV-driven oropharyngeal SCC.
Still, treatment choice should ideally be driven by clinical suitability, not by whether a patient can access private surgical technology.
This is where real-world audits have value. They can identify patterns that may not be visible in trial data. They can also support discussion about service planning, referral pathways, and equitable access to specialist procedures.
For New Zealand cancer care, the review raises a practical question: if a subgroup of patients can safely receive surgery alone, how can the system make that pathway available fairly?
How these outcomes compare with trial evidence
The comparison with E3311 gives the review a useful reference point. E3311 is often discussed in relation to transoral surgery and risk-adapted adjuvant therapy for HPV-positive oropharyngeal cancer.
In the Northland MDM review, the surgery-alone rate of 34% stood out beside the 11% reported in E3311. That difference suggests the local MDM process may have selected a favourable surgical group particularly well.
Still, comparisons between a retrospective review and a clinical trial should remain cautious. The populations, inclusion rules, clinical thresholds, and health system factors differ. A higher surgery-alone rate is encouraging, but it does not prove that the local pathway is better for every patient.
What it does show is that carefully selected real-world patients can achieve results that are at least comparable with trial expectations, and in some respects may appear better. That is a useful finding because clinicians must make decisions in real clinics, not only in trial protocols.
The best reading is balanced: trial evidence provides structure, while real-world MDM review shows how that structure performs in practice.
The main takeaway for Stage 1 HPV oropharyngeal SCC care
The review presented by Dr John Chaplin offers a clear message. In Stage 1 HPV-driven oropharyngeal SCC, the quality of selection matters.
The northern regional MDM did not treat all patients the same, and that was the point. Surgical and non-surgical patients differed by age, deprivation, treatment setting, and access to TORS. Within the selected surgical group, a substantial proportion avoided adjuvant treatment. Those who had surgery alone had a lower and shorter supplementary feeding burden than patients who needed treatment after surgery.
The findings support a practical view of care:
Surgery alone can be valuable for selected patients
Adjuvant treatment increases the supportive care burden
MDM selection can produce strong real-world outcomes
Access to TORS and public-private differences need attention
Trial data and real-world audit should be read together
For patients and whānau, this does not mean one treatment is always best. It means the treatment plan should come from careful staging, expert review, and honest discussion of both cure and side effects.
For clinicians and services, the review is a reminder that good outcomes depend on more than evidence alone. They depend on the pathway that turns evidence into care.
This article is for general information only and is not a substitute for personalised medical advice. Treatment decisions for oropharyngeal cancer should be made with the treating specialist team.
Comments